ArticleScientific reports2025
Evaluation of antimicrobial and antibiofilm activities of peptide Impatiens balsamina-M1 and Zinc oxide nanoparticles against Helicobacter pylori.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Helicobacter pylori is a common human pathogen associated with chronic gastritis, peptic ulcers, and gastric cancer. The bacterium’s ability to form biofilms and acquire antibiotic resistance, especially against clarithromycin and metronidazole, has considerably reduced the efficacy of conventional treatment. These difficulties highlight the urgent need for new antimicrobial strategies that can disrupt biofilms and combat antibiotic resistance. Antimicrobial peptides and nanoparticles have emerged as promising options in this context. The antibacterial and antibiofilm properties of Impatiens balsamina-M1 (Ib-M1), green-synthesised Zinc Oxide nanoparticles (ZnO NPs), and their combination against H. pylori were assessed in this study, representing the assessment of their effects on biofilm formation, virulence gene expression, and host cell invasion. MIC (minimum inhibitory concentration) values confirmed stronger antibacterial activity of ZnO NPs (16–32 µg/mL) than Ib-M1 (500–1000 µg/mL). For H. pylori strain BY-1, the combination had an additive effect, while in other strains, it was indifferent. SEM demonstrated significant biofilm disruption, and biofilm assays showed lower MBEC (minimum biofilm eradication concentration) values with the combination. qRT-PCR revealed downregulation of cagA, vacA, ureA, hspR, and spoT, especially when treatments were combined. Flow cytometry showed that bacterial invasion into AGS gastric adenocarcinoma cells dropped from 21.9 (control) to 3.6% with the combination. All three treatments exhibited acceptable cytotoxicity, with the combination showing significantly less toxic effects on AGS cells. Together, these findings suggest that these antimicrobial agents provide a promising, environmentally friendly approach to combat antibiotic-resistant H. pylori, efficiently reducing host cell invasion, virulence gene expression, growth, and biofilm formation while maintaining low cytotoxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.